129 related articles for article (PubMed ID: 36792355)
21. IL-17A-producing CD8
Picard FSR; Lutz V; Brichkina A; Neuhaus F; Ruckenbrod T; Hupfer A; Raifer H; Klein M; Bopp T; Pfefferle PI; Savai R; Prinz I; Waisman A; Moos S; Chang HD; Heinrich S; Bartsch DK; Buchholz M; Singh S; Tu M; Klein L; Bauer C; Liefke R; Burchert A; Chung HR; Mayer P; Gress TM; Lauth M; Gaida M; Huber M
Gut; 2023 Aug; 72(8):1510-1522. PubMed ID: 36759154
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
[TBL] [Abstract][Full Text] [Related]
23. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma.
Van den Broeck A; Sergeant G; Ectors N; Van Steenbergen W; Aerts R; Topal B
Eur J Surg Oncol; 2009 Jun; 35(6):600-4. PubMed ID: 19131205
[TBL] [Abstract][Full Text] [Related]
24. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Groot VP; Gemenetzis G; Blair AB; Ding D; Javed AA; Burkhart RA; Yu J; Borel Rinkes IH; Molenaar IQ; Cameron JL; Fishman EK; Hruban RH; Weiss MJ; Wolfgang CL; He J
Ann Surg Oncol; 2018 Aug; 25(8):2475-2483. PubMed ID: 29948425
[TBL] [Abstract][Full Text] [Related]
25. cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer.
Kabashima A; Matsuo Y; Ito S; Akiyama Y; Ishii T; Shimada S; Masamune A; Tanabe M; Tanaka S
Sci Rep; 2022 Jun; 12(1):10466. PubMed ID: 35773436
[TBL] [Abstract][Full Text] [Related]
26. Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens.
Walters DM; Stokes JB; Adair SJ; Stelow EB; Borgman CA; Lowrey BT; Xin W; Blais EM; Lee JK; Papin JA; Parsons JT; Bauer TW
PLoS One; 2013; 8(10):e77065. PubMed ID: 24204737
[TBL] [Abstract][Full Text] [Related]
27. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
28. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment.
Wang L; Liu Y; Dai Y; Tang X; Yin T; Wang C; Wang T; Dong L; Shi M; Qin J; Xue M; Cao Y; Liu J; Liu P; Huang J; Wen C; Zhang J; Xu Z; Bai F; Deng X; Peng C; Chen H; Jiang L; Chen S; Shen B
Gut; 2023 May; 72(5):958-971. PubMed ID: 35688610
[TBL] [Abstract][Full Text] [Related]
29. Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma.
Xia T; Xu P; Mou Y; Zhang X; Song S; Zhou Y; Lu C; Zhu Q; Xu Y; Jin W; Wang Y
World J Surg Oncol; 2023 Jun; 21(1):191. PubMed ID: 37349737
[TBL] [Abstract][Full Text] [Related]
30. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Groot VP; Rezaee N; Wu W; Cameron JL; Fishman EK; Hruban RH; Weiss MJ; Zheng L; Wolfgang CL; He J
Ann Surg; 2018 May; 267(5):936-945. PubMed ID: 28338509
[TBL] [Abstract][Full Text] [Related]
31. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.
Thomas RM; Truty MJ; Kim M; Kang Y; Zhang R; Chatterjee D; Katz MH; Fleming JB
Ann Surg Oncol; 2015; 22(6):1884-92. PubMed ID: 25404477
[TBL] [Abstract][Full Text] [Related]
32. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma.
Haeberle L; Cacciato Insilla A; Kapp AC; Steiger K; Schlitter AM; Konukiewitz B; Demir IE; Friess H; Esposito I
Histol Histopathol; 2021 Jul; 36(7):733-742. PubMed ID: 33769550
[TBL] [Abstract][Full Text] [Related]
33. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
Front Immunol; 2021; 12():643529. PubMed ID: 33679807
[No Abstract] [Full Text] [Related]
34. Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer.
Jing Y; Wang F; Zhang K; Chen Z
BMC Med Genomics; 2022 Apr; 15(1):96. PubMed ID: 35468838
[TBL] [Abstract][Full Text] [Related]
35. MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negative Patients.
Kubo H; Hiroshima Y; Mori R; Saigusa Y; Murakami T; Yabushita Y; Sawada Y; Homma Y; Kumamoto T; Matsuyama R; Endo I
Ann Surg Oncol; 2019 Dec; 26(13):4506-4514. PubMed ID: 31489551
[TBL] [Abstract][Full Text] [Related]
36. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
Front Immunol; 2021; 12():719105. PubMed ID: 35111149
[TBL] [Abstract][Full Text] [Related]
37. Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma.
Pan X; Zhou J; Xiao Q; Fujiwara K; Zhang M; Mo G; Gong W; Zheng L
J Hematol Oncol; 2021 Nov; 14(1):184. PubMed ID: 34727952
[TBL] [Abstract][Full Text] [Related]
38. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK
Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173
[TBL] [Abstract][Full Text] [Related]
39. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A
Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294
[TBL] [Abstract][Full Text] [Related]
40. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
